Calumet Specialty Products Partners Crecimiento futuro

Future controles de criterios 3/6

Calumet Specialty Products Partners se prevé un crecimiento anual de los beneficios y los ingresos de 25.6% y 5.6%, respectivamente, mientras que el BPA aumentará de grow a 23.1%.

Información clave

31.2%

Tasa de crecimiento de los beneficios

33.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Oil and Gas	0.8%
Tasa de crecimiento de los ingresos	4.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	17 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Will Want Calumet Specialty Products Partners' (NASDAQ:CLMT) Growth In ROCE To Persist

Apr 01

Calumet Specialty Products: Huge Increases In Cash Flows May Be Imminent [Downgrade]

Mar 18

LVS Advisory - Calumet: Fits Firmly Within The 'Moderate Risk, High Reward' Portfolio Bucket

Feb 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CLMT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,918	180	-123	178	4
12/31/2025	4,341	105	-7	152	4
12/31/2024	3,995	42	-164	131	4
12/31/2023	4,181	47	-287	-15	N/A
9/30/2023	4,204	42	-458	-57	N/A
6/30/2023	4,220	-43	-604	-39	N/A
3/31/2023	4,626	-40	-523	77	N/A
12/31/2022	4,686	-170	-436	101	N/A
9/30/2022	4,553	-179	-288	137	N/A
6/30/2022	4,263	-143	-113	132	N/A
3/31/2022	3,646	-205	-140	3	N/A
12/31/2021	3,148	-255	-127	-44	N/A
9/30/2021	2,836	-250	-75	-32	N/A
6/30/2021	2,529	-355	-109	-77	N/A
3/31/2021	2,176	-275	-3	32	N/A
12/31/2020	2,268	-146	19	63	N/A
9/30/2020	2,489	-103	41	103	N/A
6/30/2020	2,851	-53	87	153	N/A
3/31/2020	3,294	-73	84	145	N/A
12/31/2019	3,453	-43	137	192	N/A
9/30/2019	3,526	14	223	258	N/A
6/30/2019	3,550	3	155	188	N/A
3/31/2019	3,598	-31	80	122	N/A
12/31/2018	3,498	-50	25	75	N/A
9/30/2018	3,533	-86	-118	-52	N/A
6/30/2018	3,606	-95	-88	-14	N/A
3/31/2018	3,628	-34	-76	-5	N/A
12/31/2017	3,764	-29	-96	-26	N/A
9/30/2017	3,702	-58	N/A	20	N/A
6/30/2017	3,642	-66	N/A	20	N/A
3/31/2017	3,648	-222	N/A	20	N/A
12/31/2016	3,474	-290	N/A	4	N/A
9/30/2016	3,551	-363	N/A	62	N/A
6/30/2016	3,724	-382	N/A	165	N/A
3/31/2016	3,907	-239	N/A	231	N/A
12/31/2015	3,930	-99	N/A	376	N/A
9/30/2015	4,654	-101	N/A	464	N/A
6/30/2015	5,190	-43	N/A	451	N/A
3/31/2015	5,469	-54	N/A	277	N/A
12/31/2014	5,791	-125	N/A	227	N/A
9/30/2014	5,695	-78	N/A	-13	N/A
6/30/2014	5,525	-122	N/A	-60	N/A
3/31/2014	5,444	-106	N/A	113	N/A
12/31/2013	5,421	-11	N/A	39	N/A
9/30/2013	5,399	50	N/A	201	N/A
6/30/2013	5,074	128	N/A	370	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: CLMT(25.1% al año) es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: CLMTSe prevé que los beneficios de la empresa (25.1% al año) crezcan más deprisa que el mercado US (14.6% al año).

Beneficios de alto crecimiento: CLMTSe espera que los beneficios de la empresa crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: CLMT(6.8% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: CLMTSe prevé que los ingresos de la empresa (6.8% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de CLMT se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Calumet Specialty Products Partners Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase from loss to US$0.226 profit

Consensus EPS estimates upgraded to US$0.18 loss

Consensus EPS estimates increase by 12%

Price target decreased to US$25.28

Price target increased to US$26.20

Consensus estimates of losses per share improve by 11%

Recent updates

Consensus EPS estimates increase from loss to US$0.226 profit

Investors Will Want Calumet Specialty Products Partners' (NASDAQ:CLMT) Growth In ROCE To Persist

Consensus EPS estimates upgraded to US$0.18 loss

Calumet Specialty Products: Huge Increases In Cash Flows May Be Imminent [Downgrade]

New major risk - Earnings quality

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Calumet Specialty Products Partners, L.P. to Report Q4, 2023 Results on Feb 23, 2024

LVS Advisory - Calumet: Fits Firmly Within The 'Moderate Risk, High Reward' Portfolio Bucket

Calumet Specialty Products: Falling Knifes And Investor Irrationality

Chairman of the Board of Calumet GP exercised options and sold US$269k worth of stock

Consensus EPS estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Calumet Specialty Products Partners, L.P. to Report Q3, 2023 Results on Nov 09, 2023

Calumet Specialty Products Partners, L.P. to Appoint David Lunin as EVP on January 1, 2024

Calumet Specialty Products Partners, L.P. Announces CFO Changes

Second quarter 2023 earnings: EPS misses analyst expectations

Calumet Specialty Products Partners, L.P. to Report Q2, 2023 Results on Aug 04, 2023

Insider recently bought US$82k worth of stock

First quarter 2023 earnings released: EPS: US$0.35 (vs US$1.18 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 25% undervalued

Price target decreased to US$25.28

Key Executive recently bought US$57k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Calumet Specialty Products Partners, L.P. Appoints Steve Mawer as Chairman of the Board, Effective from January 1, 2023

Calumet Specialty Products Partners, L.P. to Report Q3, 2022 Results on Nov 09, 2022

Calumet Specialty Products Blasted Off, The Cash Flow Went Solar

Price target increased to US$26.20

Insider recently bought US$101k worth of stock

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.97 loss in 2Q 2021)

Calumet Specialty Q2 2022 Earnings Preview

Calumet Specialty Products Partners, L.P. Announces Additions to Board of Directors

The Final Countdown For Calumet Specialty Products' Launch Continues

Calumet Specialty Products Partners, L.P. to Report Q2, 2022 Results on Aug 05, 2022

Consensus estimates of losses per share improve by 11%

Consensus estimates of losses per share improve by 14%

It's The Final Countdown For Calumet Specialty Products

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Less than half of directors are independent

Consensus forecasts updated

Calumet Specialty Products Partners, L.P. to Report Q1, 2022 Results on May 06, 2022

Consensus forecasts updated

Calumet Specialty Products Partners, L.P. Always Landing On Its Feet

Full year 2021 earnings: EPS and revenues miss analyst expectations

Calumet Specialty Products Partners, L.P. Announces That Fred Fehsenfeld, Chairman of the Board of the General Partner Elected to Retire Effective May 1, 2022

Calumet Specialty Products Partners, L.P. to Report Q4, 2021 Results on Feb 25, 2022

Evaluating Calumet's Apparent Conservative Equity Valuation

Forecast breakeven date pushed back to 2023

Calumet Specialty Products Calls All Aboard

Price target decreased to US$19.10

Third quarter 2021 earnings released: EPS US$0.64 (vs US$0.70 loss in 3Q 2020)

Frantic Buying At Calumet Specialty Products

Price target increased to US$9.20

For Calumet, Progress Marches

Second quarter 2021 earnings released: US$0.97 loss per share (vs US$0.044 profit in 2Q 2020)

Consensus forecasts updated

Price target increased to US$7.00

Consensus EPS estimates fall to -US$2.31

More About Calumet's Duo Threaded Growth Businesses

Consensus forecasts updated

Consensus forecasts updated

First quarter 2021 earnings released: US$1.82 loss per share (vs US$0.18 loss in 1Q 2020)

Calumet Specialty EPS misses by $1.25, beats on revenue

Consensus forecasts updated

Price target increased to US$5.00